A healthcare cyberattack exposed records linked to more than 1,400 U.S. patients, underscoring growing cybersecurity risks across the medical sector and healthcare supply chain nationwide.
The FDA is preparing to review GRAIL’s Galleri multi-cancer blood test, a technology designed to detect signals from many cancers through one blood sample soon.
FDA expanded Mounjaro’s approved use to reduce cardiovascular risk in certain adults with type 2 diabetes, broadening its role beyond glucose control and weight management.
FDA is seeking public feedback on regulating generative AI-enabled medical devices while balancing innovation, clinical evidence, cybersecurity, and patient safety for doctors and patients nationwide.
FDA approved the first oral drug specifically indicated for adult dermatomyositis, giving patients with the rare inflammatory disease a new treatment option nationwide for patients.
Biotech company uniQure has applied for U.S. approval of an experimental Huntington’s gene therapy after FDA reversed an earlier position on its development this year.
NIH researchers have identified rare antibodies that could help explain and potentially treat alpha-gal syndrome, an allergy linked to tick bites and meat and food.
Rising newborn vitamin K shot refusals are renewing concerns among U.S. doctors about preventable bleeding, with CDC guidance emphasizing protection immediately after birth for infants.
FDA added a boxed warning to Injectafer labeling over low blood phosphate risks, advising monitoring for patients receiving repeat courses or facing risk factors closely.
U.S. doctors are urging patients to follow updated fall 2026 flu and COVID vaccine guidance as federal recommendations continue changing ahead of respiratory season now.
